Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free CYCN Stock Alerts

Cyclerion Therapeutics (CYCN) Financials

Cyclerion Therapeutics logo
$3.64 -0.02 (-0.55%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$3.64 0.00 (0.00%)
As of 07/17/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Cyclerion Therapeutics

Annual Income Statements for Cyclerion Therapeutics

This table shows Cyclerion Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -115 -123 -78 -52 -44 -5.26 -3.06 -3.53
Consolidated Net Income / (Loss)		 -115 -123 -78 -52 -44 -5.26 -3.06 -3.53
Net Income / (Loss) Continuing Operations		 -115 -123 -81 -52 -18 -13 -3.06 -3.53
Total Pre-Tax Income 		-115 -123 -81 -52 -19 -13 -3.06 -3.53
Total Operating Income		 -115 -125 -81 -55 -19 -13 -3.63 -4.97
Total Gross Profit		 0.00 4.51 2.30 3.94 0.30 0.00 2.00 2.07
Total Revenue		 0.00 4.51 2.30 3.94 0.30 0.00 2.00 2.07
Operating Revenue		 - 4.51 2.30 3.94 0.30 0.00 2.00 2.07
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 115 130 84 59 19 13 5.63 7.05
Selling, General & Admin Expense		 28 34 29 21 13 8.13 5.34 6.09
Research & Development Expense		 88 95 56 38 5.98 1.52 0.29 0.96
Total Other Income / (Expense), net		 0.00 2.03 0.59 3.56 0.00 0.36 0.57 1.45
Other Income / (Expense), net		 - - - - - 0.36 0.57 1.45
Basic Earnings per Share		 ($4.21) ($4.49) ($2.56) ($1.32) ($20.28) ($2.25) ($1.21) ($1.11)
Weighted Average Basic Shares Outstanding		 27.38M 27.38M 34.05M 39.14M 2.17M 2.34M 2.52M 3.18M
Diluted Earnings per Share		 ($4.21) ($4.49) ($2.56) ($1.32) ($20.28) ($2.25) ($1.21) ($1.11)
Weighted Average Diluted Shares Outstanding		 27.38M 27.38M 34.05M 39.14M 2.17M 2.34M 2.52M 3.18M
Weighted Average Basic & Diluted Shares Outstanding		 27.38M 27.38M 30.40M - 43.52M 2.71M 2.71M 4.33M

Quarterly Income Statements for Cyclerion Therapeutics

This table shows Cyclerion Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 7.57 -1.69 -1.54 -1.32 -0.72 0.53 -1.43 -0.39 -0.98 -0.66 -3.18
Consolidated Net Income / (Loss)		 7.57 -1.69 -1.54 -1.32 -0.72 0.53 -1.43 -0.32 -0.98 -0.80 -3.18
Net Income / (Loss) Continuing Operations		 -5.91 -1.70 0.00 0.00 -0.72 -2.33 -1.43 0.00 -0.98 -2.55 -3.18
Total Pre-Tax Income 		-5.91 -1.55 -1.54 -1.32 -0.72 0.53 -1.43 -1.73 -0.98 0.69 -3.18
Total Operating Income		 -6.02 -1.80 -1.62 -1.38 -1.13 0.50 -1.46 -1.67 -1.01 -0.84 -3.21
Total Gross Profit		 0.00 - 0.00 0.00 0.19 1.81 0.08 0.00 0.88 1.20 0.00
Total Revenue		 0.00 - 0.00 0.00 0.19 1.81 0.08 0.00 0.88 1.20 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 6.02 1.80 1.62 1.38 1.32 1.30 1.54 1.77 1.88 1.86 3.21
Selling, General & Admin Expense		 2.13 1.77 1.57 1.28 1.24 1.25 1.50 1.71 1.53 1.34 2.48
Research & Development Expense		 0.58 0.02 0.04 0.11 0.08 0.06 0.04 0.06 0.35 0.52 0.73
Total Other Income / (Expense), net		 0.11 0.25 0.08 0.06 0.41 0.03 0.03 0.03 0.03 1.36 0.03
Other Income / (Expense), net		 0.11 - 0.08 0.06 0.41 0.03 0.03 0.03 0.03 1.36 0.03
Basic Earnings per Share		 $3.10 ($0.72) ($0.62) ($0.53) ($0.29) $0.21 ($0.56) ($0.11) ($0.30) ($0.14) ($0.76)
Weighted Average Basic Shares Outstanding		 2.44M 2.34M 2.49M 2.51M 2.53M 2.52M 2.56M 3.07M 3.23M 3.18M 4.21M
Diluted Earnings per Share		 $2.72 ($0.72) ($0.62) ($0.53) ($0.29) $0.21 ($0.56) ($0.11) ($0.30) ($0.14) ($0.76)
Weighted Average Diluted Shares Outstanding		 2.79M 2.34M 2.49M 2.51M 2.53M 2.52M 2.56M 3.07M 3.23M 3.18M 4.21M
Weighted Average Basic & Diluted Shares Outstanding		 2.45M 2.71M 2.71M 2.71M 2.71M 2.71M 3.21M 3.34M 3.93M 4.33M 4.33M

Annual Cash Flow Statements for Cyclerion Therapeutics

This table details how cash moves in and out of Cyclerion Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.00 103 -44 -4.27 -41 -5.81 -4.34 0.01
Net Cash From Operating Activities		 -98 -102 -72 -37 -41 -21 -4.33 -3.31
Net Cash From Continuing Operating Activities		 -98 -102 -72 -37 -41 -21 -4.33 -3.31
Net Income / (Loss) Continuing Operations		 -115 -123 -78 -52 -44 -5.26 -3.06 -3.53
Consolidated Net Income / (Loss)		 -115 -123 -78 -52 -44 -5.26 -3.06 -3.53
Depreciation Expense		 1.53 2.70 2.30 0.47 0.07 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 13 20 7.23 18 2.36 -13 0.22 0.59
Changes in Operating Assets and Liabilities, net		 3.43 -2.35 -4.22 -3.47 1.04 -2.52 -1.50 -0.37
Net Cash From Investing Activities		 -3.44 -6.72 0.02 1.46 0.00 10 0.00 0.00
Net Cash From Continuing Investing Activities		 -3.44 -6.72 0.02 1.46 0.00 10 0.00 0.00
Purchase of Property, Plant & Equipment		 -3.44 -6.89 -1.52 -0.01 0.00 0.00 0.00 0.00
Sale of Property, Plant & Equipment		 0.00 0.17 1.54 1.46 0.00 0.00 0.00 0.00
Divestitures		 - - - - 0.00 10 0.00 0.00
Net Cash From Financing Activities		 101 212 28 31 0.03 5.02 0.00 3.32
Net Cash From Continuing Financing Activities		 101 212 28 31 0.03 5.02 0.00 3.32
Issuance of Common Equity		 0.00 176 25 31 0.03 5.02 0.00 1.38
Other Financing Activities, net		 101 46 0.00 - - - 0.00 1.95
Effect of Exchange Rate Changes		 - - - 0.00 0.00 0.01 -0.01 0.00

Quarterly Cash Flow Statements for Cyclerion Therapeutics

This table details how cash moves in and out of Cyclerion Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 3.47 -1.54 -1.88 -1.11 -1.72 0.36 -0.97 -0.63 1.56 -1.33 -0.42
Net Cash From Operating Activities		 -6.94 -1.54 -1.87 -1.11 -1.72 0.36 -0.97 -0.50 -0.26 -1.58 -1.18
Net Cash From Continuing Operating Activities		 -6.94 -1.54 -1.87 -1.11 -1.72 0.36 -0.97 -0.50 -0.26 -1.58 -1.18
Net Income / (Loss) Continuing Operations		 7.57 -1.69 -1.54 -1.32 -0.72 0.53 -1.43 -0.32 -0.98 -0.80 -3.18
Consolidated Net Income / (Loss)		 7.57 -1.69 -1.54 -1.32 -0.72 0.53 -1.43 -0.32 -0.98 -0.80 -3.18
Non-Cash Adjustments To Reconcile Net Income		 -13 -0.17 0.18 0.19 -0.25 0.10 0.11 0.14 0.09 0.25 0.01
Changes in Operating Assets and Liabilities, net		 -1.97 0.32 -0.51 0.03 -0.74 -0.27 0.35 -0.32 0.62 -1.03 1.99
Net Cash From Investing Activities		 10 - 0.00 - - - 0.00 - - - -0.07
Net Cash From Continuing Investing Activities		 10 - 0.00 - - - 0.00 - - - -0.07
Purchase of Property, Plant & Equipment		 - - - - - - 0.00 - - - -0.07
Net Cash From Financing Activities		 - - 0.00 - - - 1.38 -0.13 1.83 0.25 0.83
Net Cash From Continuing Financing Activities		 - - 0.00 - - - 0.00 -0.13 1.83 0.25 0.83
Other Financing Activities, net		 - - - - - - 0.00 - 1.83 0.25 0.83

Annual Balance Sheets for Cyclerion Therapeutics

This table presents Cyclerion Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 7.40 186 115 59 18 13 9.58 9.99
Total Current Assets		 0.88 101 59 55 15 8.02 4.23 4.64
Cash & Equivalents		 0.00 95 54 54 13 7.57 3.23 3.24
Accounts Receivable		 0.00 1.47 0.13 0.10 0.10 0.00 0.56 1.00
Prepaid Expenses		 0.87 1.97 0.82 0.93 0.81 0.44 0.42 0.38
Other Current Assets		 0.01 2.86 3.16 0.47 0.54 0.01 0.02 0.01
Plant, Property, & Equipment, net		 6.50 12 6.87 0.07 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.03 74 50 3.81 3.26 5.35 5.35 5.35
Long-Term Investments		 - - - - 0.00 5.35 5.35 5.35
Total Liabilities & Shareholders' Equity		 7.40 186 115 59 18 13 9.58 9.99
Total Liabilities		 18 89 56 11 7.63 2.09 0.73 0.90
Total Current Liabilities		 18 18 17 11 7.63 2.09 0.73 0.90
Short-Term Debt		 - 0.00 3.51 - - - - 0.00
Accounts Payable		 2.78 3.31 1.44 1.83 2.97 1.20 0.39 0.51
Accrued Expenses		 15 12 8.72 9.26 4.66 0.89 0.34 0.39
Other Current Liabilities		 0.00 3.42 3.29 - - - - 0.00
Total Noncurrent Liabilities		 0.00 71 39 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.00 71 39 - - - - 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -10 98 59 48 10 11 8.85 9.09
Total Preferred & Common Equity		 -10 98 59 48 10 11 8.85 9.09
Preferred Stock		 - - - - 0.00 0.00 0.00 0.00
Total Common Equity		 -10 98 59 48 10 11 8.85 9.09
Common Stock		 0.00 183 223 263 270 276 276 280
Retained Earnings		 0.00 -86 -163 -215 -259 -264 -267 -271
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.02 -0.03 -0.02 -0.02 -0.01 0.00 0.00

Quarterly Balance Sheets for Cyclerion Therapeutics

This table presents Cyclerion Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 15 11 10 8.90 9.85 9.37 10 8.51
Total Current Assets		 9.86 6.01 4.72 3.55 4.50 4.02 5.07 3.09
Cash & Equivalents		 9.11 5.70 4.59 2.87 3.64 3.01 4.57 2.82
Accounts Receivable		 0.00 - - 0.04 0.58 0.53 0.10 0.00
Prepaid Expenses		 0.73 0.31 0.12 0.62 0.26 0.46 0.39 0.26
Other Current Assets		 0.03 0.01 0.01 0.01 0.02 0.03 0.01 0.01
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07
Total Noncurrent Assets		 5.35 5.35 5.35 5.35 5.35 5.35 5.35 5.35
Long-Term Investments		 5.35 5.35 5.35 5.35 5.35 5.35 5.35 5.35
Total Liabilities & Shareholders' Equity		 15 11 10 8.90 9.85 9.37 10 8.51
Total Liabilities		 2.34 1.44 1.28 0.70 1.07 0.80 0.88 1.71
Total Current Liabilities		 2.34 1.44 1.28 0.70 1.07 0.80 0.88 1.71
Short-Term Debt		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable		 0.81 0.74 0.65 0.30 0.48 0.46 0.48 0.46
Accrued Expenses		 1.53 0.70 0.63 0.40 0.58 0.34 0.40 1.26
Other Current Liabilities		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital Lease Obligations		 - - - - 0.00 0.00 - 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 13 9.92 8.78 8.20 8.78 8.57 9.54 6.79
Total Preferred & Common Equity		 13 9.92 8.78 8.20 8.78 8.57 9.54 6.79
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 13 9.92 8.78 8.20 8.78 8.57 9.54 6.79
Common Stock		 276 276 276 276 278 278 280 281
Retained Earnings		 -263 -266 -267 -268 -269 -269 -270 -274
Accumulated Other Comprehensive Income / (Loss)		 -0.02 -0.02 0.00 0.00 0.00 0.00 - 0.00

Annual Metrics And Ratios for Cyclerion Therapeutics

This table displays calculated financial ratios and metrics derived from Cyclerion Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 27,468,904.00 33,961,868.00 43,315,745.00 43,494,184.00 2,445,096.00 2,710,096.00 3,925,314.00
DEI Adjusted Shares Outstanding		 0.00 1,373,445.00 1,698,093.00 2,165,787.00 2,174,709.00 2,445,096.00 2,710,096.00 3,925,314.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -89.56 -45.82 -23.85 -20.27 -2.15 -1.13 -0.90
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% -49.06% 71.69% -92.47% -100.00% 0.00% 3.70%
EBITDA Growth		 0.00% -7.57% 35.45% 30.70% 66.24% 31.84% 75.72% -15.41%
EBIT Growth		 0.00% -8.49% 35.01% 32.08% 66.41% 32.08% 75.72% -15.41%
NOPAT Growth		 0.00% -8.49% 35.01% 32.08% 66.41% 30.15% 71.99% -37.07%
Net Income Growth		 0.00% -6.73% 36.75% 33.62% 14.66% 88.06% 41.92% -15.41%
EPS Growth		 0.00% -6.65% 42.98% 48.44% 14.66% 88.91% 46.22% 8.26%
Operating Cash Flow Growth		 0.00% -4.83% 29.08% 49.62% -11.21% 47.69% 79.60% 23.52%
Free Cash Flow Firm Growth		 0.00% 0.00% 33.40% 55.88% 44.01% 34.26% 57.15% 16.50%
Invested Capital Growth		 0.00% 79.35% 321.14% -219.81% 48.73% 44.27% 116.41% 84.70%
Revenue Q/Q Growth		 0.00% 48.94% -36.99% 11.26% -80.83% 100.00% 930.93% 204.55%
EBITDA Q/Q Growth		 0.00% 3.55% 8.33% 7.54% 59.09% -1,115.56% 48.41% -0.34%
EBIT Q/Q Growth		 0.00% 3.34% 8.31% 8.13% 59.05% -1,115.56% 48.41% -0.34%
NOPAT Q/Q Growth		 0.00% 3.34% 8.31% 8.13% 59.05% -831.10% 38.78% -36.88%
Net Income Q/Q Growth		 0.00% 3.79% 8.07% 14.06% 7.47% 51.20% 42.11% -60.44%
EPS Q/Q Growth		 0.00% 0.00% 3.03% 5.04% 7.47% 49.21% 42.11% 5.13%
Operating Cash Flow Q/Q Growth		 0.00% 0.96% 10.08% 12.91% 3.76% 20.57% 30.49% -141.02%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -2,005.36% 9.95% 48.18% -881.32% 22.22% -69.54%
Invested Capital Q/Q Growth		 0.00% -102.93% -41.73% -119.22% 24.50% -3.03% 1,216.67% 230.26%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00%
EBITDA Margin		 0.00% -2,714.38% -3,439.37% -1,388.20% -6,220.54% 0.00% -152.85% -170.11%
Operating Margin		 0.00% -2,774.28% -3,539.42% -1,400.18% -6,242.42% 0.00% -181.40% -239.78%
EBIT Margin		 0.00% -2,774.28% -3,539.42% -1,400.18% -6,242.42% 0.00% -152.85% -170.11%
Profit (Net Income) Margin		 0.00% -2,729.27% -3,388.59% -1,310.17% -14,841.08% 0.00% -152.85% -170.11%
Tax Burden Percent		 100.00% 100.00% 96.44% 100.03% 237.75% 41.79% 100.00% 100.00%
Interest Burden Percent		 100.00% 98.38% 99.28% 93.54% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -4,354.04% 0.00% 0.00% 0.00% 0.00% -912.48%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -4,326.98% 0.00% 0.00% 0.00% 0.00% -911.93%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 4,255.07% 0.00% 0.00% 0.00% 0.00% 873.14%
Return on Equity (ROE)		 1,103.42% -281.86% -98.97% -95.87% -150.19% -48.42% -30.36% -39.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -1,337.79% 0.00% 0.00% 0.00% -1,656.94% -971.98%
Operating Return on Assets (OROA)		 0.00% -128.98% -53.84% -63.19% -47.90% 0.00% -26.64% -36.07%
Return on Assets (ROA)		 0.00% -126.89% -51.55% -59.12% -113.88% 0.00% -26.64% -36.07%
Return on Common Equity (ROCE)		 1,103.42% -281.86% -98.97% -95.87% -150.19% -48.42% -30.36% -39.34%
Return on Equity Simple (ROE_SIMPLE)		 1,103.42% -125.87% -130.78% -107.05% -421.72% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -81 -88 -57 -39 -13 -9.07 -2.54 -3.48
NOPAT Margin		 0.00% -1,942.00% -2,477.59% -980.12% -4,369.70% 0.00% -126.98% -167.84%
Net Nonoperating Expense Percent (NNEP)		 0.00% -71.05% -27.06% -23.94% -92.36% 28.91% -4.81% -0.55%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -80.31% -28.70% -38.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 763.35% 1,255.05% 523.08% 4,329.29% 0.00% 267.10% 293.54%
R&D to Revenue		 0.00% 2,110.94% 2,457.06% 954.74% 2,013.13% 0.00% 14.30% 46.24%
Operating Expenses to Revenue		 0.00% 2,874.28% 3,639.42% 1,500.18% 6,342.42% 0.00% 281.40% 339.78%
Earnings before Interest and Taxes (EBIT)		 -115 -125 -81 -55 -19 -13 -3.06 -3.53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -114 -122 -79 -55 -18 -13 -3.06 -3.53
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.76 1.75 1.54 2.73 0.73 0.99 0.55
Price to Tangible Book Value (P/TBV)		 0.00 0.76 1.75 1.54 2.73 0.73 0.99 0.55
Price to Revenue (P/Rev)		 0.00 16.58 45.26 18.90 96.10 0.00 4.36 2.40
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 11.12 0.00 0.00 0.00 0.54 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 23.10 5.21 51.04 0.00 0.07 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.14 -0.98 -1.01 -1.15 -1.21 -1.07 -0.96
Leverage Ratio		 -0.71 2.22 1.92 1.62 1.32 1.45 1.14 1.09
Compound Leverage Factor		 -0.71 2.19 1.91 1.52 1.32 1.45 1.14 1.09
Debt to Total Capital		 0.00% 0.00% 5.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 5.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 94.43% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -0.04 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.64 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.06 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.89 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -1.79 -2.74 -3.15 -20.71 -27.90 -32.30 -35.19
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.05 5.55 3.45 5.00 1.94 3.85 5.83 5.15
Quick Ratio		 0.00 5.28 3.22 4.88 1.77 3.63 5.22 4.71
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -96 -64 -28 -16 -10 -4.44 -3.71
Operating Cash Flow to CapEx		 -2,836.04% -1,522.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.05 0.02 0.05 0.01 0.00 0.17 0.21
Accounts Receivable Turnover		 0.00 0.00 2.87 34.73 3.03 0.00 0.00 2.67
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.50 0.25 1.14 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 127.26 10.51 120.44 0.00 0.00 136.92
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 127.26 10.51 120.44 0.00 0.00 136.92
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -10 -2.16 4.77 -5.72 -2.93 -1.63 0.27 0.50
Invested Capital Turnover		 0.00 -0.72 1.76 -8.34 -0.07 0.00 -2.93 5.44
Increase / (Decrease) in Invested Capital		 0.00 8.29 6.93 -10 2.79 1.30 1.90 0.23
Enterprise Value (EV)		 0.00 -20 53 21 15 -4.73 0.14 -3.60
Market Capitalization		 0.00 75 104 75 29 8.19 8.73 4.99
Book Value per Share		 ($0.38) $3.56 $1.75 $1.11 $0.24 $4.62 $3.27 $2.31
Tangible Book Value per Share		 ($0.38) $3.56 $1.75 $1.11 $0.24 $4.62 $3.27 $2.31
Total Capital		 -10 98 63 48 10 11 8.85 9.09
Total Debt		 0.00 0.00 3.51 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -95 -51 -54 -13 -13 -8.58 -8.59
Capital Expenditures (CapEx)		 3.44 6.72 -0.02 -1.46 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -17 -12 -9.34 -9.59 -6.19 -1.63 0.27 0.50
Debt-free Net Working Capital (DFNWC)		 -17 83 45 44 7.19 5.94 3.50 3.74
Net Working Capital (NWC)		 -17 83 42 44 7.19 5.94 3.50 3.74
Net Nonoperating Expense (NNE)		 35 35 21 13 31 -3.80 0.52 0.05
Net Nonoperating Obligations (NNO)		 0.00 -100 -55 -54 -13 -13 -8.58 -8.59
Total Depreciation and Amortization (D&A)		 1.53 2.70 2.30 0.47 0.07 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -265.08% -406.66% -243.25% -2,083.84% 0.00% 13.40% 23.87%
Debt-free Net Working Capital to Revenue		 0.00% 1,840.43% 1,962.46% 1,125.62% 2,421.89% 0.00% 175.00% 180.09%
Net Working Capital to Revenue		 0.00% 1,840.43% 1,809.63% 1,125.62% 2,421.89% 0.00% 175.00% 180.09%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($89.80) ($51.20) $0.00 ($20.20) ($2.25) $0.00 ($1.11)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.39M 1.70M 0.00 2.17M 2.34M 0.00 3.18M
Adjusted Diluted Earnings per Share		 $0.00 ($89.80) ($51.20) $0.00 ($20.20) ($2.25) $0.00 ($1.11)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.39M 1.70M 0.00 2.17M 2.34M 0.00 3.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($89.80) ($51.20) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.37M 1.52M 0.00 2.18M 2.71M 0.00 4.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -81 -88 -57 -39 -13 -6.75 -2.54 -3.48
Normalized NOPAT Margin		 0.00% -1,942.00% -2,477.59% -980.12% -4,369.70% 0.00% -126.98% -167.84%
Pre Tax Income Margin		 0.00% -2,729.27% -3,513.81% -1,309.77% -6,242.42% 0.00% -152.85% -170.11%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -8.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Cyclerion Therapeutics

This table displays calculated financial ratios and metrics derived from Cyclerion Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 2,410,796.00 2,445,096.00 2,710,096.00 2,710,096.00 2,710,096.00 2,710,096.00 5,420,192.00 3,210,094.00 3,337,436.00 3,925,314.00 4,330,314.00
DEI Adjusted Shares Outstanding		 2,410,796.00 2,445,096.00 2,710,096.00 2,710,096.00 2,710,096.00 2,710,096.00 5,420,192.00 3,210,094.00 3,337,436.00 3,925,314.00 4,330,314.00
DEI Earnings Per Adjusted Shares Outstanding		 3.14 -0.69 -0.57 -0.49 -0.27 0.20 -0.26 -0.12 -0.29 -0.17 -0.73
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 351.03% -33.61% -100.00%
EBITDA Growth		 -30.77% -114.49% 52.92% 29.12% 87.76% 129.51% 7.33% -24.13% -34.99% -2.26% -122.32%
EBIT Growth		 -30.77% -114.49% 52.92% 29.12% 87.76% 129.51% 7.33% -24.13% -34.99% -2.26% -122.32%
NOPAT Growth		 -33.13% -110.14% 50.60% 25.79% 81.25% 139.93% 9.95% -20.81% 10.82% -266.93% -120.25%
Net Income Growth		 172.08% 76.52% 77.83% 68.38% -109.56% 131.29% 7.33% 75.49% -34.99% -250.75% -122.32%
EPS Growth		 156.31% 78.31% 80.63% 71.04% -110.66% 129.17% 9.68% 79.25% -3.45% -166.67% -35.71%
Operating Cash Flow Growth		 30.06% 78.12% 69.89% 83.13% 75.26% 123.36% 48.26% 54.52% 84.62% -538.61% -21.49%
Free Cash Flow Firm Growth		 -244.51% -126.58% -3.63% 94.72% 63.87% 45.23% 40.56% -733.14% 85.19% 23.87% 44.50%
Invested Capital Growth		 59.16% 44.27% 65.38% -135.23% 98.49% 116.41% 81.39% 118.53% -1,483.33% 84.70% -561.24%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 830.93% -95.52% 0.00% 0.00% 37.03% -100.00%
EBITDA Q/Q Growth		 -216.78% 69.60% 14.14% 14.27% 45.31% 173.31% -369.62% -14.84% 40.52% 153.07% -713.32%
EBIT Q/Q Growth		 -216.78% 69.60% 14.14% 14.27% 45.31% 173.31% -369.62% -14.84% 40.52% 153.07% -713.32%
NOPAT Q/Q Growth		 -222.52% 70.14% 9.91% 14.46% 18.50% 163.58% -303.17% -14.76% 39.83% -19.00% -168.05%
Net Income Q/Q Growth		 280.96% -122.39% 8.97% 14.27% 45.31% 173.31% -369.62% 77.33% -201.23% 18.14% -297.62%
EPS Q/Q Growth		 248.63% -126.47% 13.89% 14.52% 45.28% 172.41% -366.67% 80.36% -172.73% 53.33% -442.86%
Operating Cash Flow Q/Q Growth		 -5.80% 77.78% -21.41% 40.89% -55.15% 120.98% -368.89% 48.04% 47.51% -498.11% 25.52%
Free Cash Flow Firm Q/Q Growth		 -12.64% 60.74% -27.38% 90.63% -671.19% 40.48% -38.23% -31.31% 86.29% -205.86% -0.78%
Invested Capital Q/Q Growth		 -222.81% -3.03% 31.23% -2.85% 97.92% 1,216.67% -177.99% 202.39% -277.57% 230.26% -379.19%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -372.68% 29.35% -1,764.20% 0.00% -111.54% 43.20% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -581.44% 27.80% -1,798.77% 0.00% -114.97% -69.89% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -372.68% 29.35% -1,764.20% 0.00% -111.54% 43.20% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -372.68% 29.35% -1,764.20% 0.00% -111.54% -66.64% 0.00%
Tax Burden Percent		 -128.06% 109.64% 100.00% 100.00% 100.00% 100.00% 100.00% 18.69% 100.00% -115.46% 100.00%
Interest Burden Percent		 100.00% 86.02% 100.00% 100.00% 100.00% 100.00% 100.00% 105.67% 100.00% 133.59% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -379.96% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -380.42% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 364.23% 0.00%
Return on Equity (ROE)		 -73.37% -48.42% 2.15% 43.18% -50.13% -30.36% -31.48% -22.43% -24.80% -15.73% -67.77%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,656.94% 0.00% -1,867.99% 0.00% -971.98% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -6.00% 5.12% -346.17% 0.00% -7.87% 9.16% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -6.00% 5.12% -346.17% 0.00% -7.87% -14.13% 0.00%
Return on Common Equity (ROCE)		 -73.37% -48.42% 2.15% 43.18% -50.13% -30.36% -31.48% -22.43% -24.80% -15.73% -67.77%
Return on Equity Simple (ROE_SIMPLE)		 -83.78% 0.00% 1.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.21 -1.26 -1.13 -0.97 -0.79 0.50 -1.02 -1.17 -0.70 -0.84 -2.25
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -407.01% 27.80% -1,259.14% 0.00% -80.48% -69.89% 0.00%
Net Nonoperating Expense Percent (NNEP)		 67.56% -3.32% -4.50% -4.53% 0.59% 0.26% -4.08% 9.25% -3.00% 0.45% -10.85%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.14% -11.41% -11.03% -9.63% 5.67% -11.62% -13.66% -7.38% -9.22% -33.08%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 639.69% 69.10% 1,854.32% 0.00% 175.20% 112.09% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 41.75% 3.10% 44.44% 0.00% 39.77% 43.29% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 681.44% 72.20% 1,898.77% 0.00% 214.97% 155.38% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.91 -1.80 -1.54 -1.32 -0.72 0.53 -1.43 -1.64 -0.98 0.52 -3.18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.91 -1.80 -1.54 -1.32 -0.72 0.53 -1.43 -1.64 -0.98 0.52 -3.18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.64 0.73 0.87 0.71 0.86 0.99 0.77 1.09 0.80 0.55 0.99
Price to Tangible Book Value (P/TBV)		 0.64 0.73 0.87 0.71 0.86 0.99 0.77 1.09 0.80 0.55 0.99
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 36.18 4.36 3.26 0.00 11.27 2.40 3.37
Price to Earnings (P/E)		 0.00 0.00 58.20 2.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 1.72% 48.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.54 0.00 4.60 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.19 -1.21 -1.32 -1.12 -1.08 -1.07 -1.07 -1.05 -1.02 -0.96 -1.10
Leverage Ratio		 1.37 1.45 1.65 1.45 1.14 1.14 1.13 1.12 1.09 1.09 1.18
Compound Leverage Factor		 1.37 1.24 1.65 1.45 1.14 1.14 1.13 1.18 1.09 1.46 1.18
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -22.80 -25.23 -29.12 -34.29 -36.02 -31.06 -34.27 -33.39 -30.83 -33.85 -43.59
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.21 3.85 4.17 3.68 5.07 5.83 4.21 5.03 5.78 5.15 1.80
Quick Ratio		 3.89 3.63 3.95 3.58 4.17 5.22 3.96 4.41 5.32 4.71 1.65
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.51 -2.55 -3.25 -0.30 -2.35 -1.40 -1.93 -2.54 -0.35 -1.07 -1.07
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,781.82%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.02 0.17 0.20 0.00 0.07 0.21 0.22
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.46 2.67 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 38.59 136.92 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 38.59 136.92 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.59 -1.63 -1.12 -1.16 -0.02 0.27 -0.21 0.21 -0.38 0.50 -1.38
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.24 -2.93 -3.12 0.00 -3.37 5.44 -2.51
Increase / (Decrease) in Invested Capital		 2.30 1.30 2.12 -0.66 1.56 1.90 0.91 1.37 -0.36 0.23 -1.17
Enterprise Value (EV)		 -6.21 -4.73 -2.37 -3.70 -1.20 0.14 -2.21 0.99 -2.24 -3.60 -1.46
Market Capitalization		 8.24 8.19 8.67 6.23 7.02 8.73 6.78 9.34 7.68 4.99 6.71
Book Value per Share		 $5.34 $4.62 $3.66 $3.24 $3.03 $3.27 $3.24 $2.67 $2.86 $2.31 $1.57
Tangible Book Value per Share		 $5.34 $4.62 $3.66 $3.24 $3.03 $3.27 $3.24 $2.67 $2.86 $2.31 $1.57
Total Capital		 13 11 9.92 8.78 8.20 8.85 8.78 8.57 9.54 9.09 6.79
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -14 -13 -11 -9.94 -8.22 -8.58 -8.99 -8.36 -9.92 -8.59 -8.17
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.59 -1.63 -1.12 -1.16 -0.02 0.27 -0.21 0.21 -0.38 0.50 -1.45
Debt-free Net Working Capital (DFNWC)		 7.52 5.94 4.57 3.43 2.85 3.50 3.43 3.22 4.19 3.74 1.38
Net Working Capital (NWC)		 7.52 5.94 4.57 3.43 2.85 3.50 3.43 3.22 4.19 3.74 1.38
Net Nonoperating Expense (NNE)		 -12 0.44 0.41 0.35 -0.07 -0.03 0.41 -0.85 0.27 -0.04 0.93
Net Nonoperating Obligations (NNO)		 -14 -13 -11 -9.94 -8.22 -8.58 -8.99 -8.36 -9.92 -8.59 -8.17
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -12.37% 13.40% -10.04% 0.00% -55.80% 23.87% -72.65%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 1,468.04% 175.00% 164.82% 0.00% 614.98% 180.09% 68.99%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 1,468.04% 175.00% 164.82% 0.00% 614.98% 180.09% 68.99%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.11 ($0.72) ($0.62) ($0.53) ($0.29) $0.21 ($0.56) ($0.11) ($0.30) ($0.14) ($0.76)
Adjusted Weighted Average Basic Shares Outstanding		 2.44M 2.34M 2.49M 2.51M 2.53M 2.52M 2.56M 3.07M 3.23M 3.18M 4.21M
Adjusted Diluted Earnings per Share		 $2.72 ($0.72) ($0.62) ($0.53) ($0.29) $0.21 ($0.56) ($0.11) ($0.30) ($0.14) ($0.76)
Adjusted Weighted Average Diluted Shares Outstanding		 2.79M 2.34M 2.49M 2.51M 2.53M 2.52M 2.56M 3.07M 3.23M 3.18M 4.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.72) $0.00 $0.00 $0.00 $0.21 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.45M 2.71M 2.71M 2.71M 2.71M 2.71M 3.21M 3.34M 3.93M 4.33M 4.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.90 -1.26 -1.13 -0.97 -0.79 0.35 -1.02 -1.17 -0.70 -0.59 -2.25
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -407.01% 19.46% -1,259.14% 0.00% -80.48% -48.92% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -372.68% 29.35% -1,764.20% 0.00% -111.54% 57.71% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Cyclerion Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cyclerion Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Cyclerion Therapeutics' net income appears to be on a downward trend, with a most recent value of -$3.53 million in 2025, falling from -$115.25 million in 2018. The previous period was -$3.06 million in 2024. View Cyclerion Therapeutics' forecast to see where analysts expect Cyclerion Therapeutics to go next.

Cyclerion Therapeutics' total operating income in 2025 was -$4.97 million, based on the following breakdown:
  • Total Gross Profit: $2.07 million
  • Total Operating Expenses: $7.05 million

Over the last 7 years, Cyclerion Therapeutics' total revenue changed from $0.00 in 2018 to $2.07 million in 2025, a change of 207,400,000.0%.

Cyclerion Therapeutics' total liabilities were at $900 thousand at the end of 2025, a 24.1% increase from 2024, and a 95.0% decrease since 2018.

In the past 7 years, Cyclerion Therapeutics' cash and equivalents has ranged from $0.00 in 2018 to $94.90 million in 2019, and is currently $3.24 million as of their latest financial filing in 2025.

Over the last 7 years, Cyclerion Therapeutics' book value per share changed from -0.38 in 2018 to 2.31 in 2025, a change of -706.7%.


Related Companies

Financial statements for NASDAQ:CYCN last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
This same-day trade is getting a lot of attention
Zero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...
Base Camp Trading | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Ex-CIA Insider: “Prepare for a Mid-Term Meltdown”
Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...
Paradigm Press | Sponsoredtc pixel